MorphoSys AG (WBO:MOR) 1-Year ROIIC % : 3,461.62% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. MorphoSys AG's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 3,461.62%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for MorphoSys AG's 1-Year ROIIC % or its related term are showing as below:

WBO:MOR's 1-Year ROIIC % is ranked better than
97.26% of 1462 companies
in the Biotechnology industry
Industry Median: -2.96 vs WBO:MOR: 3461.62

MorphoSys AG 1-Year ROIIC % Historical Data

The historical data trend for MorphoSys AG's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG 1-Year ROIIC % Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

1-Year ROIIC %

Get a 7-Day Free Trial

-105.24

58.59

-33.06

-2,362.36

3,461.62

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
1-Year ROIIC %	Get a 7-Day Free Trial															-2,362.36	-42.12	-23.52	-	3,461.62

Competitive Comparison of MorphoSys AG's 1-Year ROIIC %

For the Biotechnology subindustry, MorphoSys AG's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's 1-Year ROIIC % falls into.

MorphoSys AG 1-Year ROIIC % Calculation

MorphoSys AG's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %	=	1-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	1-Year Incremental Invested Capital
	=	( -249.3006928 (Dec. 2023) - 1902.8598865 (Dec. 2022) )	/	( 1366.795 (Dec. 2023) - 1428.967 (Dec. 2022) )
	=	-2152.1605793	/	-62.172
	=	3,461.62%^***

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

MorphoSys AG (WBO:MOR) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

MorphoSys AG 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » 1-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.